Do you still think Pieris Pharmaceuticals Inc (NASDAQ:PIRS) is worth a look?
In yesterday’s Wall Street session, Pieris Pharmaceuticals Inc (NASDAQ:PIRS) shares traded at $0.18, down -5.42% from the previous session. PIRS stock price is now 5.54% away from the 50-day moving average and -24.99% away from the 200-day moving average. The market capitalization of the company currently stands at $18.11M. With the price target maintained at […]
Is Pieris Pharmaceuticals Inc. [PIRS] a good investment? Don’t be fooled by its recent momentum
The price of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) shares last traded on Wall Street rose 5.12% to $0.36. Based on available information, 2 analysts follow Pieris Pharmaceuticals Inc. (NASDAQ:PIRS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $7.00 and a low of […]
An overview of Pieris Pharmaceuticals Inc.’s (PIRS) institutional holdings
The price of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) shares last traded on Wall Street rose 16.26% to $0.37. Based on available information, 2 analysts follow Pieris Pharmaceuticals Inc. (NASDAQ:PIRS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $7.00 and a low of […]
Do you still think Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) is worth a look?
In yesterday’s Wall Street session, Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) shares traded at $0.26, up 8.06% from the previous session. As of this writing, 2 analysts cover Pieris Pharmaceuticals Inc. (NASDAQ:PIRS). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $7.00 and a […]
Stocks of Pieris Pharmaceuticals Inc. [PIRS] are gaining investors’ attention: here’s why
Stocks of Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) traded higher last session on Wall Street, down -0.62% to $0.21. According to the data, Pieris Pharmaceuticals Inc. (NASDAQ:PIRS) has 2 analysts covering its stock. The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $7.00 and […]
